| Molecule | Cat. No. | Product Name | 種 | Host | Structure | Purity | Activity | Size&Price |
|---|---|---|---|---|---|---|---|---|
| IFN-gamma | HOT IFG-H4211 | Human IFN-gamma / IFNG Protein, premium grade |  Human | HEK293 |  | MALSSDS-PAGE | $80.00 20ug | |
| IFN-gamma | HOTDMF GMP-IFGH24 | GMP Human IFN-gamma Protein | Human | HEK293 |  | SDS-PAGE | $235.00 50ug | |
| IFN-gamma | Human IFN-gamma / IFNG Protein, Research Grade | Human | HEK293 |  | MALSSDS-PAGE | $59.00 20ug | ||
| IFN-gamma | Mouse IFN-gamma / IFNG Protein, His Tag (MALS verified) |  Mouse | HEK293 |  | MALSSDS-PAGE | $290.00 100ug | ||
| IFN-gamma | Avitag IFG-M82E3 | Biotinylated Mouse IFN-gamma Protein, His,Avitag™ (MALS verified) | Mouse | HEK293 |  | MALSSDS-PAGE | $315.00 25ug |
| 英語名 | 研究コード | 研究開発ステージ | 会社 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|
| PDS-0101 | PDS-0101B; PDS-0101C; PDS-0101; PDS-0101A; PDS-101 | Phase 3 Clinical | Pds Biotechnology Corp | Anus Neoplasms; Carcinoma, Squamous Cell; Head and Neck Neoplasms; HIV Infections; Oropharyngeal Neoplasms; Papillomavirus Infections; Uterine Cervical Neoplasms; Vulvar Neoplasms | 詳細 |
| Tadekinig alfa | r-hIL-18BP; IL-18BP | Phase 3 Clinical | Ab2 Bio Ltd | Autoimmune Lymphoproliferative Syndrome; Lymphohistiocytosis, Hemophagocytic; Macrophage Activation Syndrome | 詳細 |
| SFA-002 | SFA-002; SFA002 | Phase 3 Clinical | SFA Therapeutics Inc | Arthritis, Rheumatoid; Plaque psoriasis; Psoriasis | 詳細 |
| IMNN-001 | GEN-1; EGEN-001; IMNN-001; phIL-12-005/PPC | Phase 3 Clinical | Expression Genetics | Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Colorectal Neoplasms; Cystadenocarcinoma; Cystadenocarcinoma, Serous; Fallopian Tube Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms | 詳細 |
| TAX-2 | TAX-2; AP-01; AP-02 | Phase 2 Clinical | Centre National De La Recherche Scientifique (Cnrs), University of Reims | Solid tumours; Thrombosis | 詳細 |
| OCH-NCNP1 | OCH-NCNP1 | Phase 2 Clinical | Keio University | Crohn Disease; Multiple Sclerosis | 詳細 |
| KIO-101 | PP-001; KIO-101; KIO-104 | Phase 2 Clinical | 4sc Ag | Conjunctival Diseases; Dry Eye Syndromes; Eye Diseases; Keratoconjunctivitis; Uveitis; Xerophthalmia | 詳細 |
| ASN-002 (Ascend Biopharmaceuticals) | TG-1042; Ad-IFNγ; SP-002 (Ascend Biopharmaceuticals) | Phase 2 Clinical | Transgene Sa | Basal Cell Nevus Syndrome; Carcinoma, Basal Cell; Lymphoma, B-Cell; Skin Melanoma; Skin Neoplasms; Solid tumours | 詳細 |
| Indemakitug | EI-001 | Phase 2 Clinical | Elixiron Immunotherapeutics Inc | Vitiligo | 詳細 |
| IFN-gamma-secreting HAdV antigen specific T cells (Case Comprehensive Cancer Center) | Phase 1 Clinical | Case Comprehensive Cancer Center | Hematopoietic stem cell transplantation (HSCT) | 詳細 | |
| Recombinant human interferon gamma adenovirus injection (Guangzhou Dabo Biological Products) | Phase 1 Clinical | Guangzhou Dabo Biological Products Co Ltd | Liver Neoplasms; Nasopharyngeal Neoplasms; Prostatic Neoplasms, Castration-Resistant | 詳細 | |
| TAGX-0003 | TAGX-0003; CGB-600 | Phase 1 Clinical | TagCyx Biotechnologies | Alopecia Areata; Autoimmune Diseases; Cystitis, Interstitial; Skin Diseases; Vitiligo | 詳細 |
| [89Zr]Zr-DFO-emapalumab | [89Zr]Zr-DFO-emapalumab | Phase 1 Clinical | Barbara Ann Karmanos Cancer Institute | Carcinoma, Non-Small-Cell Lung | 詳細 |
| 英語名 | 研究コード | 研究開発ステージ | 会社 | オリジナル製品名 | 最初に承認をした国 | 最初の適応症 | 最初に承認を受けた会社 | 承認された日付 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cadi-05 | Cadi-05 | Approved | National Institute Of Allergy And Infectious Diseases (Niaid) | Immuvac, Leprovac, Mycidac-C | India | Leprosy; Carcinoma, Non-Small-Cell Lung | null | 1998-01-01 | Carcinoma, Non-Small-Cell Lung; Leprosy; Squamous Cell Carcinoma of Head and Neck | 詳細 |
| Propagermanium | SK-818; SK-818C | Approved | Sanwa Kagaku Kenkyusho Co Ltd | Serocion | Japan | Hepatitis B | Sanwa Kagaku Kenkyusho Co Ltd | 1994-01-01 | Hepatitis B | 詳細 |
| Emapalumab | NI-0501 | Approved | Novimmune Sa | Gamifant | United States | Lymphohistiocytosis, Hemophagocytic | Novimmune Sa | 2018-11-20 | Arthritis, Juvenile; Cytopenia; Dermatomyositis; Hematopoietic stem cell transplantation (HSCT); Immune System Diseases; Lung Diseases, Interstitial; Lupus Erythematosus, Systemic; Lymphohistiocytosis, Hemophagocytic; Macrophage Activation Syndrome; Polyendocrinopathies, Autoimmune; Rare Diseases; Sepsis; Still's Disease, Adult-Onset | 詳細 |
| Thalidomide | NSC-66847; NSC-527179; K-17; FPF-300; FPF300 | Approved | Celgene Corp | Talizer, Thalidomide Celgene, Thalidomide Pharmion, Synovir, Thalomid, Thaled | Mainland China | Leprosy, Lepromatous; Multiple Myeloma | Changzhou Pharmaceutical Factory | 1982-01-01 | Acquired Immunodeficiency Syndrome; Adenocarcinoma, Clear Cell; Adenoma, Islet Cell; Amyotrophic Lateral Sclerosis; Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Anemia, Sideroblastic; Angiodysplasia; Appendiceal Neoplasms; Arachnoiditis; Arteriovenous Malformations; Axial Spondyloarthritis; beta-Thalassemia; Burning Mouth Syndrome; Carcinoid Tumor; Carcinoma, Adenosquamous; Carcinoma, Hepatocellular; Cholangitis, Sclerosing; Colorectal Neoplasms; Cough; Endometrial Neoplasms; Endometriosis; Epilepsy; Erythema Nodosum; Gastric Antral Vascular Ectasia; Gastrointestinal Hemorrhage; Genetic Diseases, Inborn; Glioma; Graft vs Host Disease; Head and Neck Neoplasms; Hemoglobinopathies; HIV Infections; HIV Wasting Syndrome; Hodgkin Disease; Hormone-Resistant Prostate Neoplasms; Hypertension, Portal; Idiopathic Pulmonary Fibrosis; Kidney Neoplasms; Leiomyosarcoma; Leprosy, Lepromatous; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelomonocytic, Chronic; Liver Neoplasms; Lung Neoplasms | 詳細 |
